June 18, 2008 - In a new study presented at SNM’s 55th Annual Meeting, technologists are using body mass index (BMI), instead of body weight, to provide patients optimal dosing of 18-fluoro-2-deoxyglucose (FDG), a radiopharmaceutical commonly used in oncology imaging.

BMI is a calculation that takes into account both a patient’s weight and height. Traditionally, only a patient’s weight has been taken into consideration when prescribing appropriate dosage of radiopharmaceuticals for positron emission tomography (PET) and computed tomography (CT) scans.

“Using BMI allows us to more specifically adjust dosing to individual patients,” said Sarah Krumrey, a technologist in the Department of Nuclear Medicine at St. Louis University Hospital, St. Louis, Mo., and lead author of the study, Should FDG Dose Be Based on BMI Instead of Body Weight? presented at SNM’s 55th Annual Meeting, June 14–18 in New Orleans.

Current procedures for PET/CT scans with FDG use a patient’s weight as the main factor in determining the appropriate dose. The goal of this study was to compare changes in PET/CT image quality as a result of switching from a weight-adjusted to a BMI-adjusted FDG dose. A BMI-adjusted dose was used in a total of a 104 patients undergoing PET/CT exams for known or suspected cancer. In this double-blinded study, PET/CT scans were reviewed and graded to access the image quality. Switching to a BMI-adjusted dose resulted in improved image quality and lower required dosage of 18-FDG.

“Based on our study, we believe that adjusting the FDG dose according to a patient’s BMI could lead to new imaging protocols,” added Krumrey. “The results of this study—which takes into account individual patient factors—could further advance personalized medicine,” said Krumrey. “Unlike a blanket approach, this allows us to avoid unnecessary dosing and better treat the patients in our care.”

Scientific Paper 2010: S.A. Krumrey, I. Tran, P. Yost, D. Oliver, N. Nhuyen, M. Osman, F. Qazi, Nuclear Medicine, St. Louis University Hospital, St. Louis, Mo.: “Should FDG Dose Be Based on BMI Instead of Body Weight?” SNM’s 55th Annual Meeting, June 14–18, 2008.

For more information: visit www.snm.org.


Related Content

News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
News | PET Imaging

June 18, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 18, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | FDA

June 10, 2024 — Siemens Healthineers announces the Food and Drug Administration clearance of the Biograph Trinion, a ...

Time June 10, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Cardiac Imaging

April 23, 2024 — CDL Nuclear Technologies, a pioneer in advanced diagnostic solutions, is proud to announce the launch ...

Time April 23, 2024
arrow
News | FDA

January 23, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of syngo Virtual ...

Time January 23, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
News | Radiology Business

December 27, 2023 — The American Roentgen Ray Society (ARRS) announced David M. Naeger, MD, as the 2024 ARRS ...

Time December 27, 2023
arrow
News | Radiopharmaceuticals and Tracers

December 6, 2023 — Philochem AG, a wholly owned subsidiary of Philogen S.p.A., and Blue Earth Diagnostics, a Bracco ...

Time December 06, 2023
arrow
Subscribe Now